Skip Nav Destination
Issues
15 October 2009
-
Cover Image
Cover Image
![issue cover]()
APL is driven by a PML/RARA fusion that enhances self-renewal of clonogenic progenitors and blocks promyelocytes differentiation. PML/RARA binds RXR, Daxx and corepressors. Retinoic acid promotes differentiation through transcriptional activation and PML/RARA degradation by the proteasome. Arsenic primarily degrades PML/RARA, through sumoylation of its PML moiety and subsequent ubiquitination. Oncogene degradation affects self-renewal of the progenitors and tightly correlates with disease clearance and cure. For further details, please see Nasr and coworkers on page 6321 in this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Human Cancer Biology
Cancer Therapy: Preclinical
Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity
Davide Melisi; Valeria Ossovskaya; Cihui Zhu; Roberta Rosa; Jianhua Ling; Patrick M. Dougherty; Barry M. Sherman; James L. Abbruzzese; Paul J. Chiao
Imaging, Diagnosis, Prognosis
Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients
Zoran Erlic; Lisa Rybicki; Mariola Peczkowska; Henriette Golcher; Peter H. Kann; Michael Brauckhoff; Karsten Müssig; Michaela Muresan; Andreas Schäffler; Nicole Reisch; Matthias Schott; Martin Fassnacht; Giuseppe Opocher; Silke Klose; Christian Fottner; Flavio Forrer; Ursula Plöckinger; Stephan Petersenn; Dimitry Zabolotny; Oleg Kollukch; Svetlana Yaremchuk; Andrzej Januszewicz; Martin K. Walz; Charis Eng; Hartmut P.H. Neumann; for the European-American Pheochromocytoma Study Group
Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype
Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Jeffrey A. Meyerhardt; Yoshifumi Baba; Kaori Shima; Jonathan N. Glickman; Cristina R. Ferrone; Mari Mino-Kenudson; Noriko Tanaka; Glenn Dranoff; Edward L. Giovannucci; Charles S. Fuchs
Cancer Therapy: Clinical
Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
Stephen M. Ansell; Sara A. Hurvitz; Patricia A. Koenig; Betsy R. LaPlant; Brian F. Kabat; Donna Fernando; Thomas M. Habermann; David J. Inwards; Meena Verma; Reiko Yamada; Charles Erlichman; Israel Lowy; John M. Timmerman
The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial
Andrew M. Evens; William G. Spies; Irene B. Helenowski; David Patton; Stewart Spies; Borko D. Jovanovic; Sarah Miyata; Elizabeth Hamilton; Daina Variakojis; Jun Chen; Louie Naumovski; Steven T. Rosen; Jane N. Winter; Richard A. Miller; Leo I. Gordon
Correction
Advertisement
